Selecting the best-value biosimilar in emerging countries
Open Access
- 14 September 2024
- journal article
- Published by Open Exploration Publishing
- Vol. 2 (6) , 423-430
Abstract
The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cases, price is the major determinant, as budgets are chronically scarce. However, initial savings due to price reductions can be overridden if there is a lack of supply due to product shortages or withdrawals. These events can be prevented by a best-value strategy. According to the concept of best-value medicinal products, price is only one of the various criteria to be considered. The purpose of the present paper is to provide suggestions of criteria that can be useful for selecting the best-value biological in emerging countries. Six criteria, that are not limitative, have been selected as follows: standards of regulatory approval, quality of the product, good distribution practices, security of supply, pharmacovigilance, and price.Keywords
This publication has 22 references indexed in Scilit:
- Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar CompetitionJAMA Health Forum, 2024
- Copies of Biological Medicines: Similar But Not the Same?BioDrugs, 2023
- The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 CountriesBioDrugs, 2022
- Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspectiveThe Lancet Oncology, 2022
- The global landscape on interchangeability of biosimilarsExpert Opinion on Biological Therapy, 2021
- Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in IrelandInternational Journal of Clinical Pharmacy, 2021
- Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for BiologicsPharmaceutical Research, 2021
- Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American surveyPharmacoepidemiology and Drug Safety, 2019
- Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysisThe Lancet Diabetes & Endocrinology, 2019
- Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven productsmAbs, 2017